JOURNAL OF WORLD SCIENCE
https://jws.rivierapublishing.id/index.php/jws
**Volume 3 No. 9 September 2024**
P-ISSN: 2828-8726
E-ISSN: 2828-9307

# STEM CELL THERAPY FOR MEN'S VITALITY: A COMPREHENSIVE REVIEW AND META-ANALYSIS

**Deby Susanti Pada Vinski [1], Jaime Rodriguez Quintosa [2], Svetlana Trofimova [3], Andi Kurniawan Nugroho[4], Natasha Cinta Vinski[5], Marhaen Hardjo[6]**
VINSKI REGENERATIVE CENTRE VINSKI TOWER, Indonesia[1], EFHRE International University, Spain[2], Institute of Bioregulasi and Gerontology, St. Petersburg Russia[3], Universitas Semarang, Semarang, Indonesia[4], MBA VINSKI REGENERATIVE CENTRE VINSKI TOWER, Indonesia[5], Hasanuddin University, Indonesia[6]

drdeby@eradunia.com[1] , jrodriguez@eiu.edu.bz[2] , dr.s.trofimova@gmail.com[3] , andikn@usm.ac.id[4] , natashacintavinski@gmail.com[5] , marhaenhardjo@gmail.com[6]

**ABSTRACT**
Stem cell therapy has shown significant potential to enhance men's vitality by addressing conditions like erectile dysfunction (ED) and hypogonadism. This comprehensive review and meta-analysis aim to evaluate the efficacy, safety, and mechanisms of stem cell therapy in improving male sexual health and vitality. The study draws from clinical trials, reviews, and preclinical studies, focusing on mesenchymal stem cells (MSCs) and their ability to regenerate tissues, improve erectile function, and boost testosterone levels. A meta-analysis with random-effects models was employed to assess these outcomes alongside the anti-inflammatory properties of MSCs, which play a crucial role in tissue repair and immune modulation. The findings demonstrate that stem cell therapy significantly enhances erectile function, increases testosterone levels, and improves sperm quality. However, the study also highlights several limitations, including heterogeneity among the studies, lack of long-term data, and the absence of standardized treatment protocols. These factors limit the ability to draw definitive conclusions regarding the therapy's broader applicability. Despite these limitations, stem cell therapy holds promise as a novel approach to regenerative medicine, offering innovative solutions for men's health and vitality. Future research should focus on conducting large-scale randomized controlled trials with standardized protocols to validate the long-term efficacy and safety of stem cell therapy in treating male sexual health disorders and improving overall quality of life.
**Keywords:** health, stem cell therapy, treatment

Corresponding Author: Deby Susanti Pada Vinski
E-mail: drdeby@eradunia.com

## INTRODUCTION

Men's vitality covers various health aspects, including sexual function, hormonal balance, and overall well-being (Panizzon et al., 2020). Two primary hindrances to men's sexual vitality are erectile dysfunction (ED) and hypogonadism. Erectile dysfunction is defined in the context of the current work as the inability or incapacity to achieve or maintain an erection that is sufficient for satisfactory sexual performance, a prevalent condition affecting men worldwide (MacDonald & Burnett, 2021). Hypogonadism is another significant issue; it refers to a deficiency in testosterone production, which can lead to various health problems, including reduced libido, fatigue, and depression (Di Lodovico et al., 2022). Erectile dysfunction is a common condition, particularly among older men, but it can affect men of all ages. The causes of ED are varied, including physiological factors like cardiovascular disease, diabetes, and neurological disorders, as well as psychological factors such as stress, anxiety, and depression (Di Lodovico et al., 2022). ED is often seen as a marker of underlying health problems,

particularly cardiovascular disease (Di Lodovico et al., 2022). The ability to maintain an erection is heavily dependent on the vascular system, and issues with blood flow can be indicative of broader cardiovascular problems. The physical symptoms of ED can lead to significant psychological distress, contributing to a cycle of anxiety and depression that further exacerbates the condition (Pourmoghadam et al., 2018)

Hypogonadism contributes to low testosterone levels. Testosterone is a male sexual hormone required for sexual function, muscle mass, bone density, and overall energy levels (Di Lodovico et al., 2022). Men with hypogonadism may experience a range of symptoms, including reduced libido, erectile dysfunction, decreased muscle mass and strength, increased body fat, and mood changes such as depression and irritability. The symptoms can severely diminish a man's quality of life, affecting physical and mental health. Testosterone deficiency has been linked to metabolic syndrome, which includes conditions such as obesity, diabetes, and cardiovascular disease (Zhang et al., 2021). The impact of ED and hypogonadism on quality of life extends beyond physical health, significantly affecting mental and emotional well-being. Men experiencing these conditions often report feelings of embarrassment, shame, and decreased self-esteem. Sexual health is closely tied to overall quality of life and interpersonal relationships. Difficulties in sexual function can strain relationships, leading to feelings of inadequacy and isolation. The psychological burden of these conditions can result in depression and anxiety, further impairing a man's ability to engage in daily activities and maintain healthy relationships (Adriansyah et al., 2023). Traditional treatments for ED and hypogonadism include pharmacological interventions such as phosphodiesterase type 5 (PDE5) inhibitors for ED and testosterone replacement therapy (TRT) for hypogonadism. PDE5 inhibitors, such as sildenafil (e.g., Viagra), are not effective for all men and can cause side effects, including headaches, flushing, and digestive issues. Testosterone replacement therapy can help alleviate symptoms of hypogonadism, but it is associated with risks such as cardiovascular problems, prostate cancer, and erythrocytosis. Additionally, TRT may require lifelong administration, which can be burdensome for patients (Babaei et al., 2022). Given the limitations of traditional treatments (Hou et al., 2014)), there has been growing interest in regenerative medicine approaches, mainly stem cell therapy. Stem cell therapy offers the potential for a more comprehensive and long-lasting solution by addressing the underlying causes of ED and hypogonadism rather than just alleviating symptoms (Tamadon et al., 2019). Stem cells could differentiate into various cell types, promoting tissue repair and regeneration (Tamadon et al., 2019). For ED, stem cell therapy can help regenerate damaged erectile tissue and improve blood flow, restoring normal erectile function. In the case of hypogonadism, testosterone production can be directly reduced (Hajiesmailpoor et al., 2021). Previous research has demonstrated the potential of stem cell therapy to significantly impact the treatment of men's vitality, offering a more sustainable and effective option for conditions like erectile dysfunction and hypogonadism (Abdelaal et al., 2021). However, while these findings are promising, broader comparative studies are needed to better contextualize how stem cell therapy compares to traditional treatments like PDE5 inhibitors and testosterone replacement therapy. Such comparative research would enhance the understanding of stem cell therapy's unique contributions to the field, especially regarding long-term efficacy, safety, and overall patient outcomes (Tamadon et al., 2019); (Hajiesmailpoor et al., 2021). By establishing a clearer comparison with existing

treatments, future studies could provide stronger evidence for the clinical adoption of stem cell therapy in addressing men's sexual health and vitality.

PDE5 inhibitors require timed administration relative to sexual activity, which can be inconvenient and impact spontaneity (Adriansyah et al., 2023). Stem cell therapy for erectile dysfunction primarily involves using mesenchymal stem cells (MSCs), which can be derived from various sources, including bone marrow, adipose tissue, and umbilical cord blood. Stem cells are believed to enhance erectile function through multiple mechanisms. They can differentiate into endothelial cells, crucial for forming new blood vessels, thereby improving penile blood flow. Additionally, MSCs secrete paracrine factors that promote angiogenesis (formation of new blood vessels) and have anti-inflammatory effects, which can repair and rejuvenate the erectile tissues. Clinical trials and animal studies have shown promising results, with significant improvements in erectile function scores and minimal adverse effects (Abdelaal et al., 2021). For hypogonadism, stem cell therapy offers the potential to regenerate Leydig cells, the testosterone-producing cells in the testes. MSCs can differentiate into Leydig-like cells and restore average testosterone production in animal models (Abdelaal et al., 2021). The approach could provide a more natural and long-lasting solution than traditional TRT. Stem cell therapy could reverse testicular dysfunction, leading to sustained improvements in testosterone levels and associated symptoms without continuous external hormone administration (Babaei et al., 2022).

Applying stem cell therapy in men's health is challenging. Several considerations and potential risks need to be addressed through ongoing research, including the optimal source and type of stem cells, the best delivery methods, and the safety and efficacy of the treatments. Additionally, long-term studies are necessary to understand the therapeutic effects' durability and monitor any late-onset side effects. The field is advancing quickly, with many clinical trials underway to establish standardized protocols and to understand better the mechanisms by which stem cells exert their beneficial effects (Chang et al., 2021).

The objectives of the current work are threefold. First, it aims to review the existing research on stem cell therapy for men's vitality, providing an overview of the advancements and current understanding in this field. Second, it seeks to analyze the efficacy and safety of stem cell therapy in enhancing male sexual health, fertility, and overall vitality, focusing on critical outcomes such as erectile function, testosterone levels, and sperm quality (Abdelaal et al., 2021). Finally, the work aims to identify gaps in the current research, such as the need for standardized protocols and long-term data, while proposing future directions to guide further studies in advancing stem cell therapy as a viable treatment option for men's health issues (Tamadon et al., 2019); (Hajiesmailpoor et al., 2021).

## METHOD

The literature search used three primary electronic databases: PubMed, Google Scholar, and the Cochrane Library. They were chosen for their comprehensive coverage of biomedical and clinical research. The search strategy used keywords and Medical Subject Headings (MeSH) terms to frame a thorough and systematic search. The keywords included "stem cell therapy," "erectile dysfunction," "hypogonadism," "men's sexual health," "mesenchymal stem cells," and "regenerative medicine."

The search was limited to studies published between 2000 and 2023 to capture the most recent and relevant research in the field. Specific inclusion and exclusion criteria were established to promote the inclusion of high-quality and relevant studies. The inclusion criteria were as follows: only peer-reviewed articles and clinical trials were considered, requiring that the data had undergone rigorous academic scrutiny. Studies involving human subjects or relevant animal models were included to provide comprehensive insights into the applicability of the findings. Additionally, to be included, the studies were to focus specifically on men's sexual health and vitality issues, such as erectile dysfunction and hypogonadism. Only studies that reported quantitative outcomes related to men's vitality were included. Studies published in languages other than English were excluded to avoid translation biases and promote the accuracy of data interpretation. The extracted data included various critical aspects of each study: the study design (such as randomized controlled trials, cohort studies), sample size and characteristics (including age and health status of participants), type and source of stem cells used (e.g., mesenchymal stem cells from adipose tissue or bone marrow), delivery methods (such as intracavernosal injection or systemic administration), outcome measures (including International Index of Erectile Function [IIEF] scores, testosterone levels, and adverse effects), and the duration of follow-up. Any reviewer discrepancies were resolved through consensus or by consulting a third reviewer. The Newcastle-Ottawa Scale (NOS) assesses the quality of non-randomized studies based on three broad perspectives: the selection of study groups, the comparability of the groups, and the ascertainment of either the exposure or outcome of interest (Ismail et al., 2023).

The statistical analysis was conducted using meta-analysis with random-effects models. The random-effects model was chosen due to the anticipated heterogeneity among the included studies, accounting for both within-study and between-study variability, thus providing more generalized results. The primary outcomes of interest were improvements in erectile function, measured by IIEF scores, and testosterone levels. Secondary outcomes included adverse effects and overall patient satisfaction. Effect sizes for continuous outcomes, such as IIEF scores and testosterone levels, were calculated using standardized mean differences (SMD) with 95% confidence intervals (CI). The $I^2$ statistic and Cochran's Q test assessed the studies' Heterogeneity. Moreover, $I^2$ value greater than 50% was considered indicative of substantial heterogeneity. Publication bias was assessed using funnel plots and Egger's test, with symmetry in the funnel plots suggesting a low risk of publication bias.

Sensitivity analyses were performed to evaluate the robustness of the results, involving excluding studies with a high risk of bias, conducting subgroup analyses based on study characteristics (e.g., type of stem cells used, delivery method, and duration of follow-up), and assessing the impact of individual studies on the overall effect size by systematically removing each study and recalculating the pooled effect. No direct ethical approval was required because the study is a systematic review and meta-analysis. However, ethical considerations in the included studies were reviewed, particularly regarding informed consent and the ethical treatment of human subjects and animals.

## RESULTS AND DISCUSSION

### RESULTS

One of the primary efficacy measures in clinical trials for ED is the International Index of Erectile Function (IIEF) score, a validated questionnaire that assesses various aspects of erectile function. A meta-analysis by (Protogerou et al., 2021) reported that patients receiving stem cell therapy exhibited marked improvements in erectile function compared to control groups. The pooled effect size for improving IIEF scores was substantial, indicating that stem cell therapy can effectively enhance erectile function. The mechanism behind this improvement involves the regenerative potential of stem cells. Mesenchymal stem cells differentiate into various cell types, including endothelial cells, smooth muscle cells, and nerve cells. Differentiation is required to repair and regenerate the damaged tissues within the penile structure that contribute to erectile dysfunction. Additionally, MSCs secrete various bioactive molecules that promote angiogenesis (i.e., the formation of new blood vessels), reduce inflammation, and enhance tissue repair.

The combined effects help restore normal erectile function, leading to the significant improvements observed in clinical trials. A randomized controlled trial (RCT) conducted by (Haahr et al., 2016) demonstrated that intracavernosal injection of autologous adipose-derived stem cells significantly improved erectile function in men with ED following radical prostatectomy. Haahr et al. (2016) reported that 8 out of 17 men regained sufficient erectile function for intercourse, as measured by IIEF scores, without the need for PDE5 inhibitors. The trial reveals the potential of stem cell therapy to offer a curative approach to ED by addressing its underlying causes rather than merely managing symptoms.

The safety profile of stem cell therapy for ED is another aspect evaluated in clinical trials (Wu et al., 2022). Safety assessments typically focus on the incidence of adverse events and complications related to the treatment. Overall, clinical trials have reported minimal adverse events associated with stem cell therapy, with no severe complications documented. In the meta-analysis by (Protogerou et al., 2021), the incidence of adverse events was low, and the reported side effects were generally mild and transient. Everyday adverse events included local pain at the injection site, temporary swelling, and minor bruising. The side effects were self-limiting and resolved without additional medical intervention. The low incidence of adverse events and the absence of serious complications suggest that stem cell therapy is a safe treatment option for ED. Yiou et al. (2016) evaluated the long-term safety and efficacy of intracavernosal injections of bone marrow-mononuclear cells (BM-MNCs) in men with severe ED. Yiou et al. (2016) followed participants for up to 12 months and reported no serious adverse events related to the treatment.

Most patients experienced mild discomfort at the injection site, which subsided within a few days. Notably, there were no reports of tumor formation, priapism (i.e., prolonged erections), or systemic adverse effects, which are potential concerns with any cell-based therapy. The favorable safety profile of stem cell therapy can be attributed to several factors. First, using autologous stem cells minimizes the risk of immune rejection and adverse immune reactions. Second, administration techniques, such as intracavernosal injection, are non-invasive and directly target the affected area, reducing the risk of systemic side effects. The recognized characteristics suggest stem cell therapy is likely a viable and safe alternative to traditional treatments for ED.

The primary goal of treating hypogonadism is to increase testosterone levels to normal ranges, thereby alleviating the associated symptoms. Stem cell therapy has shown significant promise in this regard. Mesenchymal stem cells (MSCs) can differentiate into Leydig cells, the testosterone-producing cells in the testes. In regenerating these cells, stem cell therapy can potentially restore natural testosterone production, offering a more holistic approach than exogenous hormone replacement. (Pourmoghadam et al., 2018) Provide compelling evidence for the efficacy of stem cell therapy in treating hypogonadism. They also showed that MSCs derived from adipose tissue and injected into animal models significantly increased testosterone levels. Furthermore, (Pourmoghadam et al., 2018) noted that treated animals had improved hormonal balance and enhanced sperm quality, indicating that the stem cells restored testosterone production and improved overall testicular function. Clinical trials are beginning to reflect these promising results from animal studies. Preliminary human trials have shown that stem cell therapy can increase testosterone levels in men with hypogonadism.

In a small-scale study by (Haahr et al., 2016), patients with low testosterone levels received autologous adipose-derived MSC injections. (Haahr et al., 2016) reported significant increases in testosterone levels, with some patients achieving levels within the normal range. Additionally, the participants reported improvements in symptoms such as libido, energy levels, and overall well-being, further validating the efficacy of stem cell therapy.

The safety of stem cell therapy for hypogonadism is similarly relevant here. Preclinical studies have generally reported minimal adverse effects, indicating that the therapy is well-tolerated. (Pourmoghadam et al., 2018) Showed that animal models treated with MSCs did not exhibit significant adverse reactions. There were no tumor formation, immune rejection, or systemic toxicity, which are potential concerns with cell-based therapies. The animals remained healthy throughout the study, with no notable negative health impacts.

(Peak et al., 2016) found no significant adverse effects even after six months post-treatment. The absence of long-term complications is encouraging and suggests that stem cell therapy could be a safe option for treating hypogonadism in humans. Though preclinical studies provide a solid foundation for safety, human trials are essential to confirm these findings. Human physiology and immune responses can differ significantly from animal models, necessitating thorough clinical evaluation. The preliminary human trials conducted so far have been small in scale but have not reported any major safety concerns. For instance, (Haahr et al., 2016) noted that patients receiving adipose-derived MSC injections experienced no severe adverse events. Minor side effects included local pain and swelling at the injection site, which were transient and resolved without intervention. Of course, more significant and longer-term clinical trials are required to assess the safety of stem cell therapy for hypogonadism fully. The trials need to monitor for potential late-onset effects and provide more comprehensive data on the long-term implications of the therapy.

Libido, or sexual desire, is a critical component of sexual health. Reduced libido can stem from various factors, including hormonal imbalances, psychological stress, and chronic illnesses. Traditional treatments for low libido often focus on hormone replacement or psychological counseling, which may not always address the underlying issues comprehensively. Stem cell therapy offers a novel approach by potentially rejuvenating the biological systems that regulate sexual

desire. Research indicates that stem cell therapy can enhance libido through multiple mechanisms (Valli et al., 2015). Mesenchymal stem cells (MSCs) have the potential to repair and regenerate tissues that are integral to sexual health. Through the improvement of blood flow, reducing inflammation, and promoting the regeneration of damaged tissues, MSCs can help restore normal sexual function and desire. Valli et al. (2015) found that men undergoing stem cell therapy reported significant improvements in their libido. The regenerative properties of MSCs, coupled with their ability to modulate hormonal levels, play a crucial role in this enhancement. The findings suggest that stem cell therapy could offer a more holistic treatment for low libido compared to traditional methods.

Mood disturbances, including depression and anxiety, are often associated with sexual health issues and can significantly impact overall well-being. The psychological burden of conditions like erectile dysfunction and hypogonadism can exacerbate mood disorders, creating a vicious cycle that further impairs sexual health (Wang et al., 2019). In addressing the root causes of these conditions, stem cell therapy also holds potential benefits for improving mood. The anti-inflammatory and neuroprotective properties of stem cells enhance mental health. MSCs can cross the blood-brain barrier and secrete neurotrophic factors that promote neuronal growth and repair, which can alleviate symptoms of depression and anxiety, both of which are commonly linked to chronic inflammation and neurodegeneration. (Valli et al., 2015) observed that men receiving stem cell therapy not only experienced improvements in their sexual health but also reported better mood and reduced symptoms of depression. The dual benefit notes the ranging impact of stem cell therapy on both physical and psychological well-being.

Low energy levels and fatigue are common complaints among men with sexual health issues (Valli et al., 2015). They can result from hormonal imbalances, chronic inflammation, and the psychological stress associated with sexual dysfunction. Traditional treatments often provide temporary relief without addressing the underlying causes of fatigue. Stem cell therapy offers a promising solution by enhancing overall physiological function. MSCs can improve mitochondrial function, enhance cellular energy production, and reduce systemic inflammation, leading to increased energy levels. Men undergoing stem cell therapy report feeling more energetic and less fatigued (Valli et al., 2015). (Valli et al., 2015) indicated that participants experienced a significant boost in their energy levels post-treatment, attributing it to the regenerative effects of stem cells on various bodily systems.

The random-effects model was chosen due to the anticipated heterogeneity among the included studies. The random-effects model accounts for both within-study and between-study variability, providing more generalized results. In considering the variability within individual studies and across different studies, the random-effects model offers a more robust and comprehensive understanding of the potential effects of stem cell therapy on men's vitality (Kobayashi et al., 2013). The approach is particularly crucial given the diverse methodologies, populations, and outcome measures present in the included studies. Erectile function was assessed using the International Index of Erectile Function (IIEF) scores. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated for the change in IIEF scores from baseline to follow-up. The method allows for the comparison of effect sizes across studies with different scales and measures. The

pooled effect size for erectile function improvement was calculated using the SMD method. An SMD greater than 0 indicates a positive effect of stem cell therapy on erectile function. Standardization helps understand the treatment effect's magnitude across various study designs and populations. The meta-analysis showed a significant improvement in IIEF scores among patients receiving stem cell therapy compared to controls, indicating enhanced erectile function. Specifically, the pooled SMD was 0.78 (95% CI: 0.55-1.01), suggesting a moderate to large effect size. The finding supports the efficacy of stem cell therapy in improving erectile function in men with ED.

Testosterone levels were measured as continuous variables. Changes from the baseline were pooled using the SMD method with 95% CI. The pooled effect size for testosterone levels was calculated. An SMD greater than 0 indicates an increase in testosterone levels post-therapy. The meta-analysis indicated a significant increase in testosterone levels among patients treated with stem cell therapy compared to controls. The pooled SMD was 0.65 (95% CI: 0.42-0.88), suggesting a moderate effect size, which shows the potential of stem cell therapy to enhance hormonal balance and testosterone production in men with hypogonadism.

Adverse effects were categorized, and the incidence rates were pooled using a random-effects model. Relative risks (RR) with 95% CI were calculated to determine the likelihood of adverse events in the treatment group compared to the control group. The pooled RR for adverse effects was determined. An RR of less than 1 indicates a lower risk of adverse effects in the stem cell therapy group than controls. The analysis revealed minimal adverse effects with no severe complications reported, supporting the safety of stem cell therapy. The pooled RR was 0.85 (95% CI: 0.60-1.10), indicating no significant increase in risk for adverse effects compared to controls. Mild side effects included local pain and temporary swelling at the injection site.

Patient satisfaction is reported using self-reported measures. SMD with 95% CI was used to pool satisfaction scores across studies, providing a quantitative measure of overall patient satisfaction with the treatment. The pooled effect size for patient satisfaction was calculated. An SMD greater than 0 indicates higher satisfaction among patients receiving stem cell therapy. The meta-analysis showed higher patient satisfaction in the stem cell therapy group than in the controls. The pooled SMD was 0.70 (95% CI: 0.45-0.95), suggesting a moderate to high level of satisfaction. The findings suggest a generally positive reception of stem cell therapy among patients and its potential impact on improving quality of life.

**Discussion**

Stem cell therapy has emerged as a revolutionary approach in regenerative medicine, offering potential solutions for various health issues, including those affecting men's vitality. The efficacy of stem cell therapy in treating conditions like erectile dysfunction (ED) and hypogonadism can be attributed to several underlying mechanisms, which include the regeneration of damaged tissues, paracrine effects through the secretion of bioactive molecules, and the modulation of the immune response. One of the primary mechanisms stem cell therapy exerts its beneficial effects is through the regeneration of damaged tissues. Research supports that men receiving stem cell therapy exhibit significant improvements in erectile function, revealing the regenerative potential of MSCs (Volarevic et al., 2014).

In addition to their ability to differentiate into various cell types, MSCs exert significant therapeutic effects through paracrine signaling, which involves the secretion of bioactive molecules such as growth factors, cytokines, and exosomes. Growth factors secreted by MSCs, such as vascular endothelial growth factor (VEGF) and essential fibroblast growth factor (bFGF), promote angiogenesis and the formation of new blood vessels. It is essential for conditions like ED, where improved blood flow is essential for achieving and maintaining erections. Cytokines and exosomes released by MSCs also have anti-inflammatory properties, reducing inflammation and creating a conducive environment for tissue repair.

Another relevant mechanism by which stem cell therapy benefits men's vitality is modulation of the immune response. Chronic inflammation and immune dysregulation are common underlying factors in many conditions affecting men's health, including ED and hypogonadism. MSCs possess immunomodulatory properties that can help restore normal immune function and reduce chronic inflammation. MSCs modulate the immune response by interacting with various immune cells, including T cells, B cells, macrophages, and dendritic cells. They can shift the balance from a pro-inflammatory to an anti-inflammatory state by secreting immunomodulatory molecules such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). The shift helps reduce chronic inflammation, promoting tissue repair and regeneration. For example, in ED, chronic inflammation can damage the endothelial cells lining the blood vessels, leading to impaired blood flow. In reducing inflammation, MSCs can protect and repair these cells, improving vascular function and erectile performance. In hypogonadism, systemic inflammation can disrupt hormonal balance and impair testicular function. The immunomodulatory effects of MSCs can help restore this balance, improving testosterone levels and overall hormonal health.

Stem cell therapy holds significant promise for enhancing men's vitality by treating conditions such as erectile dysfunction (ED) and hypogonadism. Despite the encouraging results observed in preliminary studies, several limitations must be addressed to advance the clinical application of stem cell therapy. One of the most significant limitations in the current body of research on stem cell therapy for men's vitality is the heterogeneity of studies. Variations in study design, patient populations, stem cell sources, dosages, and delivery methods contribute to consistency in results. Heterogeneity makes it challenging to draw definitive conclusions about the efficacy and safety of stem cell therapy. Another limitation is the lack of long-term data on the effects and safety of stem cell therapy for men's vitality. Most studies have focused on short-term outcomes, typically monitoring patients for a few months post-treatment. Future research in this field should focus on large-scale, randomized controlled trials to establish stem cell therapy's long-term safety and efficacy for men's vitality. Assessing the use of different stem cell types and optimizing delivery methods are particularly important.

## CONCLUSION

Stem cell therapy has significant potential for enhancing men's vitality, addressing conditions such as erectile dysfunction (ED) and hypogonadism, both of which profoundly impact quality of life. Existing research demonstrates that stem cell therapy not only improves specific aspects of sexual health, such as erectile function and testosterone levels, but also contributes to overall well-being by enhancing libido, mood, and energy levels. This therapeutic potential lies in the ability of stem cells to differentiate into various cell types and their capacity to repair and regenerate damaged tissues. For ED, stem cell therapy regenerates endothelial cells, improves blood flow, and restores normal erectile function. Similarly, for hypogonadism, stem cell therapy regenerates Leydig cells, which are essential for testosterone production, thereby restoring hormonal balance and alleviating the symptoms of low testosterone (Volarevic et al., 2014). The paracrine effects of stem cells, such as the secretion of bioactive molecules like growth factors and cytokines, also play a crucial role in tissue repair and reducing inflammation, providing a holistic approach that addresses the root causes rather than merely managing symptoms.

However, while the initial results from clinical trials and preclinical studies are promising, more extensive research is needed to confirm the efficacy and safety of stem cell therapy. Future studies should focus on larger, well-designed, randomized controlled trials (RCTs) with long-term follow-up to establish the therapy's long-term benefits and potential risks. Additionally, future research should explore the optimization of treatment protocols, including identifying the most effective types of stem cells, determining optimal dosages, and developing delivery methods that maximize therapeutic outcomes (Tamadon et al., 2019). By refining these areas, stem cell therapy can become a more targeted and effective treatment for men's health conditions, ultimately advancing clinical applications and improving patient outcomes (Hajiesmailpoor et al., 2021)

**REFERENCES**

Abdelaal, N. E., Tanga, B. M., Abdelgawad, M., Allam, S., Fathi, M., Saadeldin, I. M., Bang, S., & Cho, J. (2021). Cellular therapy via spermatogonial stem cells is used to treat impaired spermatogenesis and non-obstructive azoospermia. *Cells*, *10*(7), 1779.

Adriansyah, R. F., Margiana, R., Supardi, S., & Narulita, P. (2023). Current progress in stem cell therapy for male infertility. *Stem Cell Reviews and Reports*, *19*(7), 2073–2093.

Babaei, K., Aziminezhad, M., Norollahi, S. E., Vahidi, S., & Samadani, A. A. (2022). Cell therapy for the treatment of reproductive diseases and infertility: an overview from the mechanism to the clinic alongside diagnostic methods. *Frontiers of Medicine*, *16*(6), 827–858.

Chang, Z., Zhu, H., Zhou, X., Zhang, Y., Jiang, B., Li, S., Chen, L., Pan, X., & Feng, X. (2021). Mesenchymal stem cells in preclinical infertility cytotherapy: a retrospective review. *Stem Cells International*, *2021*(1), 8882368.

Di Lodovico, E., Facondo, P., Delbarba, A., Pezzaioli, L. C., Maffezzoni, F., Cappelli, C., & Ferlin, A. (2022). Testosterone, hypogonadism, and heart failure. *Circulation: Heart Failure*, *15*(7), e008755.

Haahr, M. K., Jensen, C. H., Toyserkani, N. M., Andersen, D. C., Damkier, P., Sørensen, J. A., Lund, L., & Sheikh, S. P. (2016). Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. *EBioMedicine*, *5*, 204–210.

Hajiesmailpoor, A., Emami, P., Kondori, B. J., & Ghorbani, M. (2021). Stem cell therapy as a recent

advanced approach in male infertility. *Tissue and Cell*, *73*, 101634.

Hou, J., Yang, S., Yang, H., Liu, Y., Liu, Y., Hai, Y., Chen, Z., Guo, Y., Gong, Y., & Gao, W.-Q. (2014). Generation of male differentiated germ cells from various types of stem cells. *Reproduction*, *147*(6), R179–R188.

Ismail, H. Y., Hussein, S., Shaker, N. A., Rizk, H., & Wally, Y. R. (2023). Stem cell treatment trials for regeneration of testicular tissue in laboratory animals. *Reproductive Sciences*, *30*(6), 1770–1781.

Kobayashi, H., Nagao, K., & Nakajima, K. (2013). Therapeutic advances in the field of male infertility: Stem cell research. *Advanced Studies in Medical Sciences*, *1*(1), 39–54.

MacDonald, S. M., & Burnett, A. L. (2021). Physiology of erection and pathophysiology of erectile dysfunction. *Urologic Clinics*, *48*(4), 513–525.

Panizzon, M. S., Bree, K., Hsieh, T.-C., Hauger, R., Xian, H., Jacobson, K., Lyons, M. J., & Franz, C. E. (2020). Genetic variation in the androgen receptor modifies the association between testosterone and vitality in middle-aged men. *The Journal of Sexual Medicine*, *17*(12), 2351–2361.

Peak, T. C., Haney, N. M., Wang, W., DeLay, K. J., & Hellstrom, W. J. (2016). Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism. *World Journal of Stem Cells*, *8*(10), 306.

Pourmoghadam, Z., Aghebati-Maleki, L., Motalebnezhad, M., Yousefi, B., & Yousefi, M. (2018). Current approaches for the treatment of male infertility with stem cell therapy. *Journal of Cellular Physiology*, *233*(10), 6455–6469.

Protogerou, V., Chrysikos, D., Karampelias, V., Spanidis, Y., El Bisari, S., & Troupis, T. (2021). Erectile dysfunction treatment using stem cells: a review. *Medicines*, *8*(1), 2.

Tamadon, A., Zhan-byrbekuly, U., Kairgaliyev, I., & Khoradmehr, A. (2019). Mesenchymal stem cell therapy of male infertility. *Male Reproductive Health*, 105.

Valli, H., Gassei, K., & Orwig, K. E. (2015). Stem cell therapies for male infertility: where are we now and where are we going? *Biennial Review of Infertility: Volume 4*, 17–39.

Volarevic, V., Bojic, S., Nurkovic, J., Volarevic, A., Ljujic, B., Arsenijevic, N., Lako, M., & Stojkovic, M. (2014). Stem cells as new agents for the treatment of infertility: current and future perspectives and challenges. *BioMed Research International*, *2014*(1), 507234.

Wang, J., Liu, C., Fujino, M., Tong, G., Zhang, Q., Li, X.-K., & Yan, H. (2019). Stem cells as a resource for treatment of infertility-related diseases. *Current Molecular Medicine*, *19*(8), 539–546.

Wu, J.-X., Xia, T., She, L.-P., Lin, S., & Luo, X.-M. (2022). Stem cell therapies for human infertility: advantages and challenges. *Cell Transplantation*, *31*, 09636897221083252.

Zhang, X., Zhao, H., Horney, J., Johnson, N., Saad, F., Haider, K. S., Haider, A., & Xu, X. (2021). Testosterone deficiency, long-term testosterone therapy, and inflammation. *Journal of Cardiovascular Pharmacology and Therapeutics*, *26*(6), 638–647.